Italy's Stevanato Q4 revenue beats on BDS unit strength

Stevanato SpA

04/03/2026 11:39

Overview

Italy-based drug containment firm's Q4 revenue rose 5%, beating analyst expectations

Adjusted diluted EPS for Q4 was €0.18

Company expects fiscal 2026 revenue between €1.26 bln and €1.29 bln

Outlook

Stevanato expects 2026 revenue between €1.26 bln and €1.29 bln

Company forecasts 2026 adjusted EBITDA of €331.8 mln to €346.9 mln

Stevanato anticipates 2026 adjusted EPS between €0.59 and €0.63

Result Drivers

BDS SEGMENT GROWTH - Revenue from Biopharmaceutical and Diagnostic Solutions segment grew 10%, driven by high-value solutions

HIGH-VALUE SOLUTIONS - Revenue from high-value solutions increased 31%, representing 49% of total revenue

ENGINEERING SEGMENT DECLINE - Engineering Segment revenue decreased 23% due to lower demand in glass converting and assembly lines

Company press release: ID:nBw62FM98a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
EUR 346.50 mln
EUR 333.01 mln (9 Analysts)
Q4 EPS
EUR 0.17
Q4 Net Income
EUR 47.60 mln
Q4 Gross Profit
EUR 106.90 mln
Q4 Operating Income
EUR 70.10 mln
Q4 Pretax Profit
EUR 65.80 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Stevanato Group SpA is $28.00, about 90.1% above its March 3 closing price of $14.73

The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 32 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)